Updated on Jun 30, 2022 | Inside, Research, Your Health
The AP (Artificial Pancreas) system runs an algorithm on a smartphone that communicates with an insulin pump and an implanted glucose sensor.
Research under way at the Icahn School of Medicine at Mount Sinai is revolutionizing the management of type 1 diabetes by using novel technology that serves as an artificial pancreas and automatically enables patients to achieve more stable glucose levels 24 hours a day.
Led by Carol Levy, MD, Associate Professor of Medicine (Endocrinology, Diabetes and Bone Disease), the Icahn School of Medicine is one of nine U.S. and European sites participating in the research, and sharing a $12.7 million grant from the National Institutes of Health. Dr. Levy is one of the study’s lead investigators. (more…)
Updated on Jun 30, 2022 | Inside, Research
Researchers at Mount Sinai’s Corinne Goldsmith Dickinson Center for Multiple Sclerosis played a key role in developing a potential breakthrough treatment for progressive multiple sclerosis (MS), according to findings that were presented in October 2015 at the meeting of the European Committee for Treatment and Research in MS in Barcelona, Spain. The Center also recently received funding to lead a new international coalition tasked with developing a strategy for diagnosing progressive MS earlier. Both efforts further strengthen Mount Sinai’s reputation as a worldwide leader in MS research. (more…)
Updated on Jun 30, 2022 | Inside, Research, School
The MEGENA tool has 3D spheres that help uncover precise network clusters associated with disease progression.
Two new Big Data analysis tools that help pinpoint specific genes that are actively involved in disease progression were recently made available to the public by scientists in the Multiscale Network Modeling Laboratory at the Icahn School of Medicine at Mount Sinai.
The team, led by Bin Zhang, PhD, Associate Professor in the Department of Genetics and Genomic Sciences, published the pair of algorithm-based tools online in November 2015 in PLoS Computational Biology and in Scientific Reports, a Nature publication. The open-source tools are available to all researchers who wish to gain a better understanding of disease mechanisms in order to develop more effective drugs and create individualized treatments. (more…)
Updated on Jun 30, 2022 | Inside, Research, School
In Mount Sinai’s Branford, Connecticut, laboratory, Research Associate Courtney Pietropaolo prepares DNA samples for sequencing.
In its first full year of operation, the Mount Sinai Genetic Testing Laboratory in Branford, Connecticut, has become an integral part of the Mount Sinai Health System’s efforts to better diagnose and treat disease.
The 16,400-square-foot facility, located 85 miles from New York City, has the high-throughput equipment to sequence thousands of samples monthly to uncover variations in DNA that code for Alzheimer’s and coronary disease, and cancer, among other diseases. (more…)
Updated on Jun 30, 2022 | Inside, Research
Kavita Dharmarajan, MD, M.Sc
Advanced-stage cancer patients who received palliative care required shorter durations of radiation treatment and had shorter hospital stays, according to a recent study at the Icahn School of Medicine at Mount Sinai.
“Radiation therapy is very effective at relieving pain, but the standard two weeks of treatment may be too long or burdensome for some patients, given the state of their illnesses,” says the study’s senior author, Kavita Dharmarajan, MD, M.Sc, Assistant Professor of Radiation Oncology, and Geriatrics and Palliative Medicine, at the Icahn School of Medicine at Mount Sinai. “We showed that shorter course treatments can be equally, if not more, effective, especially when combined with other forms of therapy that put patients first, and not the tumor.” (more…)
Updated on Jun 30, 2022 | Inside, Research
Sophia Frangou, MD, PhD
Individuals whose siblings have bipolar disorder are at high risk for developing mood disorders themselves. However, siblings who remain psychiatrically healthy may have a natural ability to rewire their brains that compensates for their genetic risk. These findings, led by Sophia Frangou, MD, PhD, Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, were published in the January 5, 2016, issue of Translational Psychiatry. (more…)
